お勉強288:世界肺がん学会速報@twitter
.@AltorkiNasser just presented practice-changing, landmark CALGB140503. No difference in disease-free and overall survival between sublobar vs lobectomy for peripheral T1N0 NSCLC tumors <2 cm. 59% in SLR arm were wedges. #lungcancer #WCLC2022 @IASLC pic.twitter.com/jaA3Ss7PXc
— Jeff yang (@ChiFuJeffYang) August 8, 2022
https://twitter.com/Mat_Guc/status/1556538932367597569
Exciting from #WCLC2022
— Matthias Guckenberger (@Mat_Guc) August 8, 2022
CALGB 140503 comparing sublobar resection (mostly wedge) vs lobectomy in stage IA NSCLC
👉 identical DFS
👉 no difference in OS (numerically better in sublobar)
👉 better preservation of PF
👉 no difference in any subgroup
👉 SBRT now closer to a SoC ? pic.twitter.com/KGKbw7TPrr
https://twitter.com/Docvk2/status/1556540236720586752
Once is a chance event, twice implies needs a magnifying glass (esp if both are RCTs) #JCOG0802 #CALGB140503. Sublobar resection in small peripheral lung cancers, Is the argument settled?@IASLC #WCLC2022 @cspramesh @drsabita @BrendonStilesMD @niyogidevayani @naveenmummudi1 pic.twitter.com/YYNK7hxDRW
— Karthik V (@Docvk2) August 8, 2022
CALGB140503 2㎝以下のcT1N0M0が対象のよう
日本の手術成績と比べるとイマイチだが、
同じ技術を持ったものが葉切しても楔状切除
しても同じ、という結論なら
小さいものはSBRTでもいいんじゃない？
というのが自然な放射線腫瘍医の考え。
🗞IMPOWER 010 - adjuvant atezolizumab in completely resected IA-IIIB #lungcancer …. 👀Are those survival curves starting to separate? 👀
— Shankar Siva (@_ShankarSiva) August 8, 2022
Data still maturing, no new safety signals, exploratory subgroup PD-L1 >50% appear to benefit. @EnriquetaFelip #WCLC22 #WCLC2022 #LCSM pic.twitter.com/S2THAm4cdU
https://twitter.com/Mat_Guc/status/1556544777491030016
Interim OS analysis of IMpower010, adjuvant Atezolizumab in resected NSCLC presented at #WCLC2022
— Matthias Guckenberger (@Mat_Guc) August 8, 2022
👉 no significant OS difference
👉 trend to improved OS in PD-L1 pos, especially in min 50%
👉 no signal for benefit in PD-L1 negative patients pic.twitter.com/CrjnoQqyvw
IMpower010フォロー長期成績。
PD-L1が50％以上なら使うが、それ以外は
あまり使うような気にならないような…